Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.

O'Day, Ken; Meyer, Kellie; Miller, Ross M; Agarwal, Sonalee; Franklin, Meg

O'Day, Ken; Meyer, Kellie; Miller, Ross M; Agarwal, Sonalee; Franklin, Meg.

Affiliation

O'Day K; Xcenda, Palm Harbor, FL, USA.

J Med Econ ; 14(5): 617-27, 2011.

Article in En | MEDLINE | ID: mdl-21777161

Subject(s)

Antibodies, Monoclonal, Humanized/economics; Health Care Costs/trends; Immunosuppressive Agents/economics; Multiple Sclerosis/drug therapy; Multiple Sclerosis/prevention & control; Propylene Glycols/economics; Sphingosine/analogs & derivatives; Antibodies, Monoclonal, Humanized/therapeutic use; Cost-Benefit Analysis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents/therapeutic use; Natalizumab; Propylene Glycols/therapeutic use; Recurrence; Sphingosine/economics; Sphingosine/therapeutic use; United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Propylene Glycols / Sphingosine / Health Care Costs / Antibodies, Monoclonal, Humanized / Immunosuppressive Agents / Multiple Sclerosis Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Humans Country/Region as subject: America do norte Language: En Journal: J Med Econ Journal subject: SERVICOS DE SAUDE Year: 2011 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google